Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus

J Hyg (Lond). 1981 Oct;87(2):201-9. doi: 10.1017/s0022172400069412.


A group of 269 pupils of the Harbour and Transport Training Institute in Rotterdam (group A), aged 13-20 years, and of 109 patients of the Dr Mr Willem van den Bergh Foundation at Noordwijk (group B), aged 11-21 years, were immunized with a whole virus vaccine containing 10, 20, or 40 microgram HA of A/USSR/92/77 (H1N1) influenza virus. A booster vaccination was administered 6 weeks later with 20 microgram HA of the same virus. Many of the participants had been immunized during the two preceding years with a whole virus vaccine containing A/New Jersey/8/76 (H1N1) (A/NJ/76) virus. The side-effects, mostly of a moderate nature, increased with the dose of virus in the vaccine. In group A side effects were least frequent in the vaccinees who had never received A/NJ/76 vaccine. A single dose of A/USSR/77 vaccine did not produce satisfactory levels of homologous antibodies. After booster immunization with 20 microgram HA of A/USSR/77 virus participants showed a higher homologous antibody response in all vaccine-dose groups if they had not been immunized with A/NJ/76 virus in previous years. After primary and especially after booster immunization with A/USSR/77 virus, a very high response against A/NJ/76 virus and adequate levels of A/NJ/76 antibody were found in participants who had been immunized previously with A/NJ/76 virus. Those who had not been immunized with this virus previously showed no or a very low antibody response to A/NJ/76 virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibody Formation*
  • Child
  • Hemagglutination Inhibition Tests
  • Humans
  • Immunization* / adverse effects
  • Immunization, Secondary
  • Influenza A Virus, H1N1 Subtype*
  • Influenza A virus / immunology*
  • Influenza Vaccines / adverse effects


  • Influenza Vaccines